Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Optivia Biotechnology, a leading provider of in vitro transporter assay services and pioneers in the field of transporter biology, has signed a collaboration agreement with the US FDA to assess the effect of dietary supplements on key drug transporters. The idea is to identify potentially harmful drug-dietary supplement interactions such as an interaction with acetaminophen, and other drugs associated with liver toxicity.
Subscribe to our email newsletter
The research collaboration will start with the examination of the seven transporters cited by the International Transporter Consortium and the FDA as the most clinically relevant to transporter-related drug-drug interactions using Optivia’s novel polarised mammalian cell assays transporter technology platform.
Optivia and the FDA will then analyse and interpret the drug transporter data as preparation for publishing the results.
Optivia Biotechnology president and CEO Yong Huang said that the project advances Optivia’s position in the development of quantitative tools for optimising the safety and efficacy of drugs.